Healthcare and Pharmaceutical Sector
Moderna and Merck achieved successful Phase 3 trial results for their personalized mRNA melanoma vaccine, driving Moderna shares up 145%, while Regeneron secured FDA approval for a rare bone-growth disorder treatment. Conversely, Capricor Therapeutics faces potential FDA rejection for its Duchenne muscular dystrophy drug, and insurers are cutting Medicare Advantage plans for nearly 3 million seniors. Additionally, Providence Health Plan is shutting down insurance operations, and the White House nominated Heidi Overton to head the FDA.
Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, met its primary and secondary endpoints in a Phase 3 trial for high-risk melanoma. The trial, named INTerpath-001, evaluated 1,137 patients who had undergone surgical removal of stage IIB to IV cutaneous melanoma. Patients received either the mRNA vaccine combined with Merck's immunotherapy Keytruda or Keytruda alone. The combination regimen demonstrated statistically significant improvements in both recurrence-free survival and distant metastasis-free survival. The therapy is built from a genetic sequencing of each patient's tumor to encode up to 34 patient-specific neoantigens, training T cells to attack residual cancer cells. The announcement drove Moderna's stock up 145% to $154.48 in morning trading, while Merck shares rose 10.6% to $149.52. The companies plan to present the full dataset at an upcoming international medical meeting and discuss regulatory filing submissions with authorities.
The U.S. Food and Drug Administration issued a 30-page discussion paper seeking public feedback on a proposed regulatory framework for generative artificial intelligence-enabled medical devices. Led by the Digital Health Center of Excellence within the Center for Devices and Radiological Health, the agency is gathering input through a public docket on Regulations.gov until October 19, 2026. The proposed framework outlines a two-axis risk assessment model alongside premarket evaluations modeled on physician competency training, incorporating non-clinical benchmarking and clinical confirmation. For post-market oversight, the initiative considers foundation models and agentic AI systems. Interested parties including device manufacturers, clinicians, and researchers have until October 19, 2026, to submit comments under docket FDA-2026-N-7874.
statnews.com reports that Capricor Therapeutics faces a near-certain Food and Drug Administration rejection for its cell therapy targeting Duchenne muscular dystrophy. The company is attempting to avert the regulatory setback by submitting results from an open-label extension following a failed Phase 3 study. According to the reporting, this submission serves as a delay tactic rather than a substantive fix. Securing ultimate approval for the treatment, known as deramiocel, now requires conducting an entirely new, randomized clinical trial.